Skip to main content

Table 1 Overview of ongoing angiotensin II antagonist trials in chronic heart failure (CHF) and post-myocardial infarction (post-MI) patients

From: ELITE II and Val-HeFT are different trials: together what do they tell us?

Study Patients Comparators Size Status
OPTIMAAL Post-MI Losartan vs captopril n = 5477 Recruitment complete; end date 2002
VALIANT Post-MI Valsartan vs captopril vs combination n = 14500 Recruitment complete; end date 2003
CHARM CHF Candesartan vs placebo n = 2548 Recruitment complete; end date 2003
  CHF (ACE intolerant) Candesartan vs placebo n = 2028 Recruitment complete
  Diastolic dysfunction Candesartan vs placebo n = 3024 Recruitment complete
  1. ACE, angiotensin-converting enzyme.